Jeffrey Richard Garber, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Nodule | 9 | 2023 | 750 | 2.720 |
Why?
|
| Endocrinology | 12 | 2021 | 443 | 1.710 |
Why?
|
| Hypothyroidism | 9 | 2016 | 659 | 1.680 |
Why?
|
| Thyroxine | 7 | 2016 | 666 | 0.960 |
Why?
|
| Thyroid Neoplasms | 8 | 2021 | 2274 | 0.920 |
Why?
|
| Thyroid Diseases | 4 | 2016 | 378 | 0.890 |
Why?
|
| Iodine Radioisotopes | 4 | 2013 | 1030 | 0.710 |
Why?
|
| Goiter, Substernal | 1 | 2014 | 17 | 0.490 |
Why?
|
| Jugular Veins | 1 | 2014 | 204 | 0.440 |
Why?
|
| Disease Management | 3 | 2018 | 2450 | 0.440 |
Why?
|
| Hypercalcemia | 2 | 2012 | 405 | 0.390 |
Why?
|
| Expert Systems | 1 | 2010 | 81 | 0.380 |
Why?
|
| Biopsy, Fine-Needle | 5 | 2021 | 1093 | 0.370 |
Why?
|
| Societies, Medical | 9 | 2018 | 3740 | 0.360 |
Why?
|
| Parathyroidectomy | 1 | 2012 | 235 | 0.360 |
Why?
|
| Thyroid Hormones | 4 | 2011 | 390 | 0.360 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2012 | 155 | 0.360 |
Why?
|
| Thyrotropin | 5 | 2016 | 850 | 0.350 |
Why?
|
| Sertraline | 2 | 2010 | 206 | 0.350 |
Why?
|
| Documentation | 1 | 2015 | 865 | 0.340 |
Why?
|
| Algorithms | 13 | 2023 | 13853 | 0.320 |
Why?
|
| Radiation Protection | 1 | 2012 | 419 | 0.320 |
Why?
|
| Conflict of Interest | 2 | 2010 | 542 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 6 | 2016 | 7276 | 0.310 |
Why?
|
| Adrenocortical Adenoma | 1 | 2008 | 48 | 0.310 |
Why?
|
| Thyroid Function Tests | 3 | 2016 | 284 | 0.310 |
Why?
|
| Authorship | 1 | 2010 | 271 | 0.290 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2008 | 162 | 0.280 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1155 | 0.260 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 2003 | 24 | 0.240 |
Why?
|
| Disclosure | 1 | 2010 | 736 | 0.230 |
Why?
|
| Drug Industry | 1 | 2010 | 744 | 0.230 |
Why?
|
| Acclimatization | 1 | 2023 | 103 | 0.220 |
Why?
|
| Incidental Findings | 1 | 2008 | 688 | 0.220 |
Why?
|
| Triiodothyronine | 2 | 2016 | 494 | 0.220 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2658 | 0.220 |
Why?
|
| Physician's Role | 1 | 2010 | 942 | 0.220 |
Why?
|
| Electronics | 1 | 2023 | 322 | 0.200 |
Why?
|
| Thyrotoxicosis | 2 | 2011 | 82 | 0.190 |
Why?
|
| Computers | 1 | 2023 | 611 | 0.190 |
Why?
|
| Endocrine Surgical Procedures | 1 | 2020 | 33 | 0.190 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2266 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2020 | 11695 | 0.180 |
Why?
|
| Ganglioneuroma | 1 | 1999 | 57 | 0.170 |
Why?
|
| United States | 19 | 2023 | 69693 | 0.170 |
Why?
|
| Hyperthyroidism | 2 | 2011 | 293 | 0.170 |
Why?
|
| Prolactinoma | 1 | 1999 | 113 | 0.170 |
Why?
|
| Humans | 53 | 2023 | 742088 | 0.160 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1431 | 0.160 |
Why?
|
| Checklist | 2 | 2017 | 830 | 0.160 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2017 | 324 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 2838 | 0.160 |
Why?
|
| Ultrasonography | 2 | 2021 | 5978 | 0.150 |
Why?
|
| Models, Educational | 1 | 2020 | 377 | 0.150 |
Why?
|
| Liver | 1 | 2013 | 7470 | 0.150 |
Why?
|
| Diet Therapy | 1 | 2018 | 154 | 0.140 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2016 | 45 | 0.140 |
Why?
|
| Graves Disease | 4 | 2011 | 241 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 9185 | 0.130 |
Why?
|
| Therapeutic Equivalency | 2 | 2006 | 145 | 0.130 |
Why?
|
| Thyroidectomy | 3 | 2020 | 877 | 0.130 |
Why?
|
| Heart Failure | 1 | 2019 | 10856 | 0.130 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 127 | 0.120 |
Why?
|
| Consensus | 6 | 2020 | 2935 | 0.120 |
Why?
|
| Otolaryngology | 1 | 2020 | 644 | 0.110 |
Why?
|
| Antithyroid Agents | 2 | 2011 | 68 | 0.110 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2012 | 315 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 552 | 0.110 |
Why?
|
| Ethics, Professional | 1 | 2012 | 102 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 781 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 1066 | 0.100 |
Why?
|
| Culture | 1 | 2016 | 632 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2013 | 280 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 1999 | 1340 | 0.090 |
Why?
|
| Health Care Sector | 1 | 2012 | 194 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 744 | 0.090 |
Why?
|
| Hypoglycemic Agents | 3 | 2018 | 2866 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 77098 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 1095 | 0.090 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 2027 | 0.090 |
Why?
|
| Mass Screening | 2 | 2016 | 5238 | 0.090 |
Why?
|
| Propylthiouracil | 1 | 2009 | 69 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 2861 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2013 | 2335 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2009 | 220 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 500 | 0.080 |
Why?
|
| Medical Records | 1 | 2013 | 1413 | 0.070 |
Why?
|
| Thyroid Gland | 2 | 2013 | 1172 | 0.070 |
Why?
|
| Internet | 2 | 2023 | 3062 | 0.070 |
Why?
|
| Prediabetic State | 3 | 2018 | 493 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 53187 | 0.070 |
Why?
|
| Fluoxetine | 1 | 2010 | 749 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 1008 | 0.070 |
Why?
|
| Palpation | 1 | 2006 | 166 | 0.070 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2020 | 436 | 0.070 |
Why?
|
| Oxyphil Cells | 1 | 2006 | 57 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2012 | 3611 | 0.070 |
Why?
|
| Thymus Hyperplasia | 1 | 2005 | 30 | 0.060 |
Why?
|
| Calcitonin | 1 | 2006 | 336 | 0.060 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2006 | 143 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 780 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 282 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2010 | 1459 | 0.060 |
Why?
|
| Pregnancy | 6 | 2016 | 29087 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 2005 | 206 | 0.060 |
Why?
|
| Blood Glucose | 4 | 2020 | 6249 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 248 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 5724 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 1503 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4929 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2023 | 23320 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5611 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2009 | 1581 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 1402 | 0.050 |
Why?
|
| Life Style | 3 | 2018 | 3824 | 0.050 |
Why?
|
| Male | 10 | 2019 | 349538 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 10248 | 0.040 |
Why?
|
| Bromocriptine | 1 | 1999 | 111 | 0.040 |
Why?
|
| Synaptophysin | 1 | 1999 | 141 | 0.040 |
Why?
|
| Hormone Antagonists | 1 | 1999 | 107 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3070 | 0.040 |
Why?
|
| Female | 14 | 2016 | 379592 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15530 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 867 | 0.040 |
Why?
|
| 1-Naphthylamine | 1 | 1997 | 49 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 1999 | 318 | 0.040 |
Why?
|
| Prolactin | 1 | 1999 | 669 | 0.040 |
Why?
|
| Insulin | 3 | 2016 | 6575 | 0.040 |
Why?
|
| Adult | 10 | 2014 | 213712 | 0.030 |
Why?
|
| Costa Rica | 1 | 2016 | 177 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39004 | 0.030 |
Why?
|
| Triazines | 1 | 2018 | 316 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 381 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 974 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2003 | 2036 | 0.030 |
Why?
|
| Physicians | 1 | 2012 | 4554 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 828 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2016 | 263 | 0.030 |
Why?
|
| Obesity | 4 | 2018 | 12705 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2867 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 604 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 786 | 0.030 |
Why?
|
| Codes of Ethics | 1 | 2012 | 62 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 2275 | 0.030 |
Why?
|
| Prognosis | 2 | 2016 | 29010 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 651 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2020 | 2680 | 0.030 |
Why?
|
| Thyroid Crisis | 1 | 2011 | 8 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 1999 | 1669 | 0.030 |
Why?
|
| Middle Aged | 6 | 2013 | 213127 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 10943 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 40450 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2016 | 8541 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2016 | 866 | 0.020 |
Why?
|
| Methimazole | 1 | 2009 | 41 | 0.020 |
Why?
|
| Counseling | 1 | 2018 | 1521 | 0.020 |
Why?
|
| Calcium | 1 | 2003 | 5753 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 11001 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 12958 | 0.020 |
Why?
|
| Research Personnel | 1 | 2012 | 573 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 29717 | 0.020 |
Why?
|
| Liver Failure | 1 | 2009 | 240 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 1887 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 839 | 0.020 |
Why?
|
| Adolescent | 3 | 2011 | 85649 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2068 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 1239 | 0.020 |
Why?
|
| Publishing | 1 | 2012 | 833 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20086 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2005 | 274 | 0.010 |
Why?
|
| Comorbidity | 1 | 2018 | 10372 | 0.010 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 279 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 12164 | 0.010 |
Why?
|
| Blood Physiological Phenomena | 1 | 2003 | 55 | 0.010 |
Why?
|
| Information Systems | 1 | 2005 | 410 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2003 | 180 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4604 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 3507 | 0.010 |
Why?
|
| Parathyroid Glands | 1 | 2003 | 509 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2003 | 594 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1988 | 1525 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1988 | 1178 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 1185 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2005 | 1264 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1988 | 1413 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2003 | 530 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 880 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 1204 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15244 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1359 | 0.010 |
Why?
|
| Hypertension | 1 | 2018 | 8455 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 1284 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 1179 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1997 | 114 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 3701 | 0.010 |
Why?
|
| Medical Errors | 1 | 2005 | 1296 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 3248 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2003 | 1801 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 5180 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 4646 | 0.010 |
Why?
|
| Time Factors | 2 | 2014 | 40054 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1997 | 1458 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1999 | 35342 | 0.010 |
Why?
|
| Communication | 1 | 2005 | 3728 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 5095 | 0.010 |
Why?
|
| Carcinoma | 1 | 2001 | 2374 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15108 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8621 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 15994 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 8925 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 6608 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 57683 | 0.000 |
Why?
|
| Aged | 3 | 2005 | 162944 | 0.000 |
Why?
|
| Child | 1 | 2011 | 77478 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 14720 | 0.000 |
Why?
|
| Risk | 1 | 1988 | 9679 | 0.000 |
Why?
|